ArticleNature communications2023
Rapid emergence of extensively drug-resistant Shigella sonnei in France.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Antimicrobial resistance in community-acquired enteric pathogens among children aged ≤ 10-years in low-and middle-income countries: a systematic review and meta-analysis.Frontiers in microbiology · 2025Pooled it
- Whole genome sequencing analysis of antibiotic resistant genes of Shigella species: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Review
- Review
- Escalation of CTX-M-producing extensively drug-resistantMicrobiology spectrum · 2026Article
- Third-generation cephalosporin-induced L-form transition inMicrobiology spectrum · 2026Article
- Investigation of an outbreak ofMicrobial genomics · 2026Article
- First report of anMicrobiology spectrum · 2026Article
- Investigation of the azithromycin resistance rate and related genes involved in this resistance in clinical Shigella species collected from children with diarrhea in Ahvaz, Southwest Iran.Molecular biology reports · 2026Article
- Anti-Shigella activity and killing kinetics of compounds from MMV Pathogen and COVID Boxes: Identifying leads against Shigellosis.Current research in pharmacology and drug discovery · 2026Article
- Isolation and characterization of lyticFrontiers in cellular and infection microbiology · 2026Article
- Genomic insights into selected multidrug-resistant and ESBL-producing uropathogenicFrontiers in microbiology · 2026Article
- Genomic characterisation and antimicrobial resistance ofFrontiers in cellular and infection microbiology · 2026Article
- The natural history of the emergence of sexually transmissible shigellosis.Microbial genomics · 2026Review
- A public resource of 15 genomically characterized representative strains ofMicrobial genomics · 2026Article
- Quantifying plasmid movement in drug-resistant Shigella species using phylodynamic inference.PLoS pathogens · 2025Article
- Epidemiological Characteristics, Antibiotic Resistance Patterns and Genomic Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Extended spectrum β-lactamase and integron genes among Shigella flexneri and Shigella sonnei isolated from children with diarrhea in shiraz, Southwest Iran.BMC pediatrics · 2025Article
- Enhanced virulence and stress tolerance are signatures of epidemiologically successful Shigella sonnei.Nature communications · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Shigella sonnei, the main cause of bacillary dysentery in high-income countries, has become increasingly resistant to antibiotics. We monitored the antimicrobial susceptibility of 7121 S. sonnei isolates collected in France between 2005 and 2021. We detected a dramatic increase in the proportion of isolates simultaneously resistant to ciprofloxacin (CIP), third-generation cephalosporins (3GCs) and azithromycin (AZM) from 2015. Our genomic analysis of 164 such extensively drug-resistant (XDR) isolates identified 13 different clusters within CIP-resistant sublineage 3.6.1, which was selected in South Asia ∼15 years ago. AZM resistance was subsequently acquired, principally through IncFII (pKSR100-like) plasmids. The last step in the development of the XDR phenotype involved various extended-spectrum beta-lactamase genes (bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.